Theromics
West Bridgewater, US · Founded 2016 · Delaware corporation · 2 known investors
Find your way into Theromics
230 people in our graph share verified history with the Theromics team — schools, employers, funds. One of them is your warm intro.
Paxton Majorunlockedknows Damian Dupuy · together at Brown University, Alpert Medical School / RIH (overlapped)
×5knows the team · via Brown University, Alpert Medical School / RIH
×3knows the team · via Queen's University
×3knows the team · via University of Ottawa
Theromics develops protein-based injectable nanogel accelerants (HeatSYNC and CryoSYNC) that improve energy transfer in soft tissue to make thermal ablation procedures larger, more spherical, and more effective, and to combine ablation with localized drug or immunotherapy delivery. It targets interventional oncology and conditions such as uterine fibroids, endometriosis, and breast cancer, and was spun out of Brown University.
Founders & leadership
Theromics was founded in 2016 by Damian Dupuy.
DD
Damian DupuyinFounder · Chief Scientific OfficerDamian Dupuy is an executive at Theromics developing biopolymers with thermal properties for medical applications including interventional oncology, women's health, and drug delivery.
AC
Andrew C. ZeringueinChief Executive Officer
WK
William Keun Chan ParkNamed on SEC filing
EW
Edward WalshNamed on SEC filing
Investors · 2
Funding
SEC filings, press & company announcements$2.3M disclosed across 4 of 5 rounds · 2018–2023
- Undisclosed amountSeedJan 2022Source ↗
▶$1.1MraisedMay 2023 · 16 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMay 2023 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John BrooksDirector
- Charles R. Williams, IIIDirector
- Damian DupuyExecutive Officer, Director
- Joseph AmaralDirector
- Ronald MurphyExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.1M
- Minimum investment
- $1
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedOct 2020 · 17 investors · BiotechnologyRule 506(b)
▶$1MraisedOct 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William Keun Chan ParkExecutive Officer, Director
- Joseph AmaralDirector
- Ronald MurphyExecutive Officer, Director
- Damian DupuyExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1M
- Minimum investment
- $1
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$125KraisedAug 2019 · 2 investors · BiotechnologyRule 506(b)
▶$125KraisedAug 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William Keun Chan ParkExecutive Officer, Director
- Joseph AmaralDirector
- Ronald MurphyExecutive Officer, Director
- Damian DupuyExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $125K
- Minimum investment
- $1
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$100KraisedJul 2018 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Damian DupuyExecutive Officer, Director
- William Keun Chan ParkExecutive Officer, Director
- Edward WalshExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $100K
- Minimum investment
- $1
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Phinomics4 shared keywordsPhinomics is a cancer drug discovery platform that captures extrachromosomal circular DNA (the "Circulome") at high resolution from matched tumor and normal patient samples, integrating it with DNA, RNA, epigenetics, and proteomics into a multi-omic knowledge graph. It applies explainable AI to this data to identify novel therapeutic targets, resistance mechanisms, and patient stratification biomarkers for oncology therapeutics development.
XDemics4 shared keywordsXDemics develops cell culture and biomanufacturing technologies for generating mammalian cells at high densities for advanced therapy production. The company's HDCR platform and related products enable researchers and GMP facilities to produce T cell, stem cell, and viral-based therapies with improved quality and consistency.
Tagomics4 shared keywordsTagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.
Companies competing with Theromics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase ISTTR | 2021 | $256K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Theromics do?
- Theromics develops protein-based injectable nanogel accelerants (HeatSYNC and CryoSYNC) that improve energy transfer in soft tissue to make thermal ablation procedures larger, more spherical, and more effective, and to combine ablation with localized drug or immunotherapy delivery. It targets interventional oncology and conditions such as uterine fibroids, endometriosis, and breast cancer, and was spun out of Brown University.
- Who founded Theromics?
- Theromics was founded by Damian Dupuy in 2016.
- Who are Theromics's investors?
- Theromics's investors include Beacon Angels, Maroon Venture Partners Fund.
- How much funding has Theromics raised?
- Theromics has disclosed $2.3M raised across 4 of its 5 known rounds.
- Where is Theromics headquartered?
- Theromics is headquartered in West Bridgewater, US.